Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umberto Vitolo

Showing results (91-100 of 212) with videos related to

Pageof 22
Sort By:
Blood Cancer Journal|June 28, 2018
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studiesAyed O Ayed, Annalisa Chiappella, Levi Pederson, et al.
Blood Advances|March 31, 2022
Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphomaAnas Younes, John M Burke, Catherine Diefenbach, et al.
Leukemia & Lymphoma|September 27, 2019
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?Mattia Novo, Grzegorz S Nowakowski, Thomas M Habermann, et al.
Leukemia & Lymphoma|June 21, 2013
Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease statusAlessandro Busca, Clara Pecoraro, Luisa Giaccone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano LinfomiTeodoro Chisesi, Monica Bellei, Stefano Luminari, et al.
British Journal of Haematology|December 19, 2013
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative studyAdalberto Ibatici, Gian Matteo Pica, Sandro Nati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2005
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano LinfomiPaolo G Gobbi, Alessandro Levis, Teodoro Chisesi, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemiaAlessandra Tedeschi, Francesca Ricci, Maria Cecilia Goldaniga, et al.
Ejhaem|November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trialsLale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
British Journal of Haematology|November 22, 2011
RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphomaGaetano Corazzelli, Ferdinando Frigeri, Filippo Russo, et al.
Pageof 22

Showing results (91-100 of 212) with videos related to

Sort By:
Pageof 22
Blood Cancer Journal|June 28, 2018
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studiesAyed O Ayed, Annalisa Chiappella, Levi Pederson, et al.
Blood Advances|March 31, 2022
Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphomaAnas Younes, John M Burke, Catherine Diefenbach, et al.
Leukemia & Lymphoma|September 27, 2019
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?Mattia Novo, Grzegorz S Nowakowski, Thomas M Habermann, et al.
Leukemia & Lymphoma|June 21, 2013
Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease statusAlessandro Busca, Clara Pecoraro, Luisa Giaccone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano LinfomiTeodoro Chisesi, Monica Bellei, Stefano Luminari, et al.
British Journal of Haematology|December 19, 2013
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative studyAdalberto Ibatici, Gian Matteo Pica, Sandro Nati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2005
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano LinfomiPaolo G Gobbi, Alessandro Levis, Teodoro Chisesi, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemiaAlessandra Tedeschi, Francesca Ricci, Maria Cecilia Goldaniga, et al.
Ejhaem|November 29, 2023
A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trialsLale Kostakoglu, Maurizio Martelli, Laurie H Sehn, et al.
British Journal of Haematology|November 22, 2011
RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphomaGaetano Corazzelli, Ferdinando Frigeri, Filippo Russo, et al.
Pageof 22